Abstract
Bronchopulmonary dysplasia is the most common pulmonary complication of preterm infants. The incidence of bronchopulmonary dysplasia is increasing due to improved survival of preterm infants at lower gestational ages. Bronchopulmonary dysplasia is associated with serious respiratory and neurodevelopmental problems during childhood. Advances in our understanding of its pathogenesis and recognition that the ‘new’ bronchopulmonary dysplasia is secondary to developmental arrest during canalicular stages of lung development, have made it possible to explore avenues for its prevention and management. This review examines the evidence for various preventative strategies and provides current information on potential future therapies including cytokine targeted and gene therapy, angiogenic therapy and other molecular agents for the prevention of bronchopulmonary dysplasia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
